Author Page for Chatnapa Duangdee

Actions:

View:
Selected
Original List
All Versions Hide All Versions
All Abstracts Hide All Abstracts

(Rank)

Heterologous Ad26.Cov2.S Booster after Primary Bbibp-Corv Vaccination Against Sars-Cov-2 Infection: 1-Year Follow-Up of a Phase 1/2 Open-Label Trialheterologous Ad26.Cov2.S Booster after Primary Bbibp-Corv Vaccination Against Sars-Cov-2 Infection: 1-Year Follow-Up of a Phase 1/2 Open-Label Trial

Number of pages: 50 Posted: 24 Jan 2024

Sant Muangnoicharoen, Rakpong Wiangcharoen, Saranath Lawpoolsri, Sira Nanthapisal, Anan Jongkaewwattana, Chatnapa Duangdee, Supitcha Kamolratakul, Viravarn Luvira, Narumon Thanthamnu, Narisara Chantratita, Arunee Thitithanyanont, T. Anh Wartel, Jean-Louis Excler, Martin F. Ryser, Chloe Leong, Tippi K. Mak and Punnee Pitisutthithum

Mahidol University - Vaccine Trial Centre, Phaholpolpayuhasena Hospital, Mahidol University, Thammasat University, National Center for Genetic Engineering and Biotechnology, Hospital for Tropical Diseases, Mahidol University, Mahidol University, Mahidol University, Mahidol University - Faculty of Tropical Medicine, Mahidol University, International Vaccine Institute, International Vaccine Institute, Janssen Global Medical Affairs, Janssen Asia Pacific Medical Affairs Operations, University of Saskatchewan and Mahidol University - Vaccine Trial Centre

Downloads 41 (1,170,409)

Chatnapa Duangdee

Hospital for Tropical Diseases

1

41

0

Scholarly Papers (1)

Heterologous Ad26.Cov2.S Booster after Primary Bbibp-Corv Vaccination Against Sars-Cov-2 Infection: 1-Year Follow-Up of a Phase 1/2 Open-Label Trialheterologous Ad26.Cov2.S Booster after Primary Bbibp-Corv Vaccination Against Sars-Cov-2 Infection: 1-Year Follow-Up of a Phase 1/2 Open-Label Trial

Abstract: